Erik van Werkhoven
Johns Hopkins University
H-index: 42
North America-United States
Top articles of Erik van Werkhoven
Young boost randomized phase III trial of high vs low boost radiation in young breast cancer patients: 10-year results
European Journal of Cancer
2024/3/1
Distinct Peripheral T-cell and NK-cell Profiles In HGBL-MYC/BCL2 versus DLBCL NOS Patients
Blood Advances
2024/1/8
Erik Van Werkhoven
H-Index: 30
P565: REAL-WORLD DATA AS SUPPLEMENTARY CONTROLS FOR THE PROSPECTIVE RANDOMIZED HOVON-103 TRIAL IN INTENSIVELY TREATED ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS
HemaSphere
2023/8/1
A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients
Blood cancer journal
2023/5/22
Erik Van Werkhoven
H-Index: 30
Immediate or delayed oncoplastic surgery after breast conserving surgery at the Netherlands Cancer Institute: a cohort study of 251 cases
Breast cancer research and treatment
2023/4
Statistical methods to analyze treatment strategies from randomized and non-randomized studies in oncology
2023
Erik Van Werkhoven
H-Index: 30
Patterns of recurrence and survival after pelvic treatment for locally advanced penile cancer
European urology open science
2023/1/1
Erik Van Werkhoven
H-Index: 30
Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study …
Blood
2023/11/28
DA-EPOCH-R for High Grade B-Cell Lymphoma Patients with MYC and BCL2 and/or BCL6 Rearrangements: Clinical Results of the Induction Phase of the HOVON-152 Trial
Blood
2023/11/28
Erik Van Werkhoven
H-Index: 30
Otto Visser
H-Index: 6
No Discernable Dysfunction of Peripheral T-Cells and NK-Cells Despite Distinct Phenotypes in MYC Rearranged Versus Non Rearranged B-Cell Lymphoma Patients
Blood
2023/11/28
Erik Van Werkhoven
H-Index: 30
High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial
NPJ Breast Cancer
2023/9/9
Erik Van Werkhoven
H-Index: 30
Judith R Kroep
H-Index: 40
P1254: RESPONSE TO DA-EPOCH-R IN PATIENTS WITH HIGH GRADE B CELL LYMPHOMA IS ASSOCIATED WITH A REDUCTION OF PD1 POSITIVE EXHAUSTED CD8 T CELLS
HemaSphere
2022/6/1
Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine-or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre …
ESMO open
2022/6/1
Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol
Breast cancer research and treatment
2022/5
FER regulates endosomal recycling and is a predictor for adjuvant taxane benefit in breast cancer
Cell reports
2022/4/5
Patients with rare cancers in the drug rediscovery protocol (DRUP) benefit from genomics-guided treatment
Clinical Cancer Research
2022/4/1
Anne Ml Jansen
H-Index: 7
Erik Van Werkhoven
H-Index: 30
Derk Jan De Groot
H-Index: 14
Mariette Labots
H-Index: 15
Hans Gelderblom
H-Index: 65
COVID-19 vaccination in patients with immune thrombocytopenia
Blood advances
2022/3/22
Differential survival and therapy benefit of patients with breast cancer are characterized by distinct epithelial and immune cell microenvironments
Clinical Cancer Research
2022/3/1
Erik Van Werkhoven
H-Index: 30
Sex differences in patients with gastrointestinal stromal tumours: do they exist and does it affect survival?
2022/12/1
The influence of docetaxel schedule on treatment tolerability and efficacy in patients with metastatic breast cancer: a systematic review and meta-analysis of randomized …
2022/1/25
Erik Van Werkhoven
H-Index: 30
Co-Authors
